Categories
· Health/Science
· Lung Cancer
· Asbestos
|
Jump to full article: PR Newswire, 2007-04-23
Author: SOURCE Rosetta Genomics Ltd
Intro: Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that it has
partnered with NYU Medical Center with the aim of developing a line of
early detection diagnostic products for lung, and Mesothelioma cancers.
The early detection test will mainly target over 45 million Americans
who are at an increased risk of lung cancer due to smoking, as well as
those who have been exposed to asbestos fibers. The test will utilize
Rosetta Genomics' proprietary protocol to extract microRNAs from a simple
blood draw.
Jump to full article » |